| HOME >> BIOLOGY >> TECHNOLOGY |
Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico
Pijls, Augusto Pichard
UPPSALA, Sweden and WILMINGTON, Mass., Oct. 19 /PRNewswire/ -- The use of fractional flow reserve (FFR) for optimizing patient outcomes is the topic of several sessions at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in Washington.
Radi Medical Systems AB, the first company to develop systems that calculate FFR with the physiologic assessment of targeted lesions, is sponsoring a breakfast session, Nine Cases That Will Change Your Practice: FFR Case Review, at 7 a.m. EDT on Oct. 23 in room No. 152 B in the Washington Convention Center. Morton J. Kern, M.D., of the University of California- Irvine, is the session's moderator, while Nico Pijls, M.D., Ph.D. of Catharina Hospital, Eindhoven, the Netherlands, and Augusto Pichard, M.D., of the Washington Hospital Center, are the participating faculty.
In addition to coverage in the case review, FFR and physiologic lesion assessment are the subject of:
-- An extensive workshop at 2 p.m. on Oct. 21 that will focus on the
basics of FFR measurement, the use of FFR in specific settings, and the
practicalities and impact of FFR in the era of drug-eluting stents
(Room 147AB)
-- A session on Oct. 22 during the "Board Review Course with Self
Assessment for Interventional Cardiology and Endovascular Medicine,
PART 3: Coronary Essentials" that will cover IVUS and physiologic
lesion assessment in clinical practice and physiologic lesion
assessment case presentations with an integrated Q&A (Room 146AB)
About FFR
FFR expresses maximum achievable blood flow in a coronary artery with abnormal stenosis as a fraction of normal maximum blood flow in the absence of a stenosis. It is calculated using an interventional guidewire with a specially designed sensor built into it. Using the well established value of 0.75, FFR is 100% specific in identifying which lesions are actually causing flow restriction and can be treated. FFR also documents the exact percentage of the reduction in flow associated with each lesion.
About Radi Medical Systems AB
Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit http://www.radi.se.
Editor's Note: Radi Medical Systems will display its latest products at booth No. 2085 at TCT 2007.
Media Contacts:
David Schull or Benjamin Carmichael
Russo Partners
+1 212-845-4271
+1 858-717-2310 (during TCT 2007)
david.schull@russopartnersllc.com
benjamin.carmichael@russopartnersllc.com
Jim Archetto
Radi Medical Systems
+1 877-337-7234 ext. 812
'/>"/>
| SOURCE Radi Medical Systems AB Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. Optimizing electroporation parameters
4. Optimizing Büchi® Rotary Evaporator Applications
5. Optimizing electroporation parameters
6. Optimizing Büchi® Rotary Evaporator Applications
7. Optimizing Bchi Rotary Evaporator Applications
8. Optimizing electroporation parameters
9. Optimizing electroporation parameters
10. Optimizing electroporation parameters
11. Optimizing electroporation parameters
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |